TY  - JOUR
AU  - Poddubnyy, Denis
AU  - Pournara, Effie
AU  - Zielińska, Agnieszka
AU  - Baranauskaite, Asta
AU  - Jiménez, Alejandro Muñoz
AU  - Sadhu, Sanchayita
AU  - Schulz, Barbara
AU  - Rissler, Michael
AU  - Perella, Chiara
AU  - Marzo-Ortega, Helena
PY  - 2021
DO  - 10.1177/1759720X211051471
SN  - 1759-720X
UR  - https://hdl.handle.net/10668/27317
T2  - Therapeutic advances in musculoskeletal disease
AB  - This study aimed to evaluate the efficacy and safety of secukinumab 150 mg compared with placebo in the management of spinal pain and disease activity in patients with axial spondyloarthritis (axSpA) at Week 8 and up to Week 24. Patients (n = 380)...
LA  - en
KW  - axial spondyloarthritis
KW  - interleukin-17A inhibitor
KW  - spinal pain
KW  - tumour necrosis factor inhibitor
TI  - Rapid improvement in spinal pain in patients with axial spondyloarthritis treated with secukinumab: primary results from a randomized controlled phase-IIIb trial.
TY  - research article
VL  - 13
ER  -